Advanced search
Publication Cover
International Journal of Hyperthermia Volume 38, 2021 - Issue 1
Submit an article Journal homepage
2,129
Views
5
CrossRef citations to date
0
Altmetric
Articles

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin in pediatric patients with peritoneal mesothelioma: a single institution experience and long term follow up

Parisa Malekzadeha Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland;b Division of Surgical Oncology, Department of Surgery, Eastern Virginia Medical School, Norfolk, VA
,
Meghan Gooda Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
&
Marybeth S. Hughesa Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland;b Division of Surgical Oncology, Department of Surgery, Eastern Virginia Medical School, Norfolk, VACorrespondence[email protected]
Pages 326-331 | Received 12 Jul 2020, Accepted 26 Nov 2020, Published online: 17 Jun 2021

References

  • Alexander HR Jr, Bartlett DL, Pingpank JF, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery. 2013;153:779–786.
  • Eltabbakh GH, Piver MS, Hempling RE, et al. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol. 1999;70:6–12.
  • Thomas A, Chen Y, Yu T, et al. Distinctive clinical characteristics of malignant mesothelioma in young patients. Oncotarget. 2015;6:16766–16773.
  • Cioffredi L-A, Jänne PA, Jackman DM. Treatment of peritoneal mesothelioma in pediatric patients. Pediatr Blood Cancer. 2009;52:127–129.
  • Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21:4560–4567.
  • Sugarbaker PH, Yan TD, Stuart OA, et al. Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;32:686–691.
  • Brigand C, Monneuse O, Mohamed F, et al. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol. 2006;13:405–412.
  • Alexander HR, Bartlett DL, Libutti SK. National Cancer Institute Experience with regional therapy for unresectable primary and metastatic cancer of the liver or peritoneal cavity. In: Markman M, editor. Regional chemotherapy: clinical research and practice. Totowa (NJ): Humana Press; 2000. p. 127–150.
  • Talerman A, Montero JR, Chilcote RR, et al. Diffuse malignant peritoneal mesothelioma in a 13-year-old girl. Report of a case and review of the literature. Am J Surg Pathol. 1985;9:73–80.
  • Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237–6242.
  • Sugalski A, Davis M, Prasannan L, et al. Clinical, histologic, and genetic features of mesothelioma in a 7-year-old child. Pediatr Blood Cancer. 2013;60:146–148.
  • Gutman SI, Steinherz PG, Gray GF. Malignant peritoneal mesothelioma in a child. Am J Dis Child. 1976;130:1268–1269.
  • Oberto C, Schwarz KB, Zambidis E, et al. Malignant peritoneal mesothelioma in a pediatric patient mimicking inflammatory bowel disease. Dig Dis Sci. 2004;49:434–437.
  • Haliloglu M, Hoffer FA, Fletcher BD. Malignant peritoneal mesothelioma in two pediatric patients: MR imaging findings. Pediatr Radiol. 2000;30:251–255.
  • Hayes-Jordan A, Green H, Ludwig J, et al. Toxicity of hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric patients with sarcomatosis/carcinomatosis: early experience and phase 1 results. Pediatr Blood Cancer. 2012;59:395–397.
  • Dhir M, Ramalingam L, Shuai Y, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion in adolescent and young adults with peritoneal metastases. Ann Surg Oncol. 2017;24:875–883.
  • Randle RW, Swett KR, Swords DS, et al. Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. Ann Surg Oncol. 2014;21:1474–1479.
  • Kusamura S, Torres Mesa PA, Cabras A, et al. The role of Ki-67 and pre-cytoreduction parameters in selecting diffuse malignant peritoneal mesothelioma (DMPM) patients for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2016;23:1468–1473.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.